Baxter BioPharma Solutions And Moderna Announce Agreement For Fill/Finish Manufacturing Of Moderna COVID-19 Vaccine In USA
Agreement to perform fill/finish services for approximately 60–90 million doses in the U.S. this year
Manufacturing will take place at Baxter BioPharma Solutions’ Indiana facility
Baxter International Inc. a global leader in sterile medication production and delivery, and Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that they have entered into an agreement for Baxter BioPharma Solutions to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021. Baxter’s BioPharma Solutions business is a premier contract manufacturing organization that specializes in parenteral (injectable) pharmaceuticals, including vaccines.
Operator
Good morning ladies and gentlemen and welcome to Baxter International s Fourth Quarter 2020 Earnings Conference Call. Your lines will remain in a listen-only mode until the question-and answer-segment of today s call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material. It should not be recorded or rebroadcast without Baxter s permission. If you have any objections, please disconnect at this time.
I would now like to turn the conference over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman you may begin.
Clare Trachtman
Vice President-Investor Relations
Good morning and welcome to our fourth quarter of 2020 earnings conference call. Joining me today are Joe Almeida, Chairman and Chief Executive Officer; and Jay Saccaro, Baxter s Chief Financial Officer. On the call this morning, we will be discussing Baxter s fourth quarter and full year 2020 financial results along